Acquiring Company
NEXGEL
Acquired Company
Celularity
LanghorneFlorham ParkBiotechnologyHealth CareBiotechnologyDescription
NEXGEL announced the completion of its acquisition of Celularity in mid-April 2026. The integration of Celularity’s employees and operations into NEXGEL’s new BioNX Surgical division is underway. The company reported revenue of $3.69 million and a net loss of $2.87 million in Q2 2026. Challenges related to the rollout and supply chain are acknowledged as part of the integration process.
Don't miss NEXGEL's next move
Get an email the moment NEXGEL makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Celularity?
Celularity was acquired by NEXGEL, based in Langhorne. The deal was reported on August 17, 2026. Nexgel is a company focused on developing and commercializing innovative hydrogel products. They specialize in regenerative biomaterials and have a range of products in various stages of development. NEXGEL is publicly traded (NXGL) and operates in Biotechnology.
When did NEXGEL acquire Celularity?
NEXGEL's acquisition of Celularity was reported on August 17, 2026. NEXGEL announced the completion of its acquisition of Celularity in mid-April 2026. The integration of Celularity’s employees and operations into NEXGEL’s new BioNX Surgical division is underway. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Celularity do?
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. It is publicly traded (CELU), operating in Biotechnology, and is based in Florham Park.